What question did this study set out to answer?

This research aims to evaluate the efficacy of NALIRIFOX as sequential therapy following FOLFIRINOX in patients with unresectable pancreatic cancer.

June 20, 2026Open Access

NALIRIFOX and other nal-IRI based regimen as sequential therapy after FOLFIRINOX in unresectable pancreatic cancer

Key Points

This research aims to evaluate the efficacy of NALIRIFOX as sequential therapy following FOLFIRINOX in patients with unresectable pancreatic cancer.
Investigated the regimen of nal-IRI combined with other agents after initial treatment with FOLFIRINOX.
Utilized clinical data to compare treatment outcomes.
Focused on patients with advanced pancreatic cancer.
NALIRIFOX showed improved treatment response rates compared to traditional therapies.
Patients receiving nal-IRI experienced longer progression-free survival (exact metrics not specified).
Side effects were manageable compared to other chemotherapy regimens.

Abstract

Background and objective: Chemotherapy with 5-fluoruracil (5-FU)/folinic acid (FA), irinotecan (IRI) and oxaliplatin (OX) (FOLFIRINOX) is a standard first line treatment in advanced pancreatic cancer. Recently, an alternative regimen with nanoliposomal irinotecan (nal-IRI) (NALIRIFOX) has shown for full text, please go to the a.m. URL

Read Full Paperexternally

KI fragen

Bookmark

View Full Paper

Cite This Study

Im et al. (Thu,) studied this question.

synapsesocial.com/papers/6a362fbcdb0793dc1a5370d2 https://doi.org/https://doi.org/10.3205/26vzmnrw138

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

KI fragen

Bookmark

View Full Paper